Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYS006 in moderate to severe inflammatory acne
NCT03497897Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of LYS006 in acne vulgaris, sponsored by Novartis. Started Sep 2018; status: completed.
02
Drugs
LYS006
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03497897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03497897.